Q3 Earnings Estimate for Electromed Issued By B. Riley

Electromed, Inc. (NYSE:ELMD) – Equities research analysts at B. Riley issued their Q3 2025 earnings per share estimates for shares of Electromed in a note issued to investors on Wednesday, February 19th. B. Riley analyst K. Bauser expects that the company will post earnings of $0.19 per share for the quarter. B. Riley currently has a “Strong-Buy” rating on the stock. B. Riley also issued estimates for Electromed’s Q4 2025 earnings at $0.22 EPS, FY2025 earnings at $0.80 EPS, Q1 2026 earnings at $0.20 EPS, Q2 2026 earnings at $0.22 EPS, Q3 2026 earnings at $0.26 EPS, Q4 2026 earnings at $0.31 EPS, FY2026 earnings at $1.00 EPS and FY2027 earnings at $1.16 EPS.

Separately, StockNews.com lowered Electromed from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 19th.

Electromed Trading Down 2.3 %

ELMD opened at $27.97 on Monday. The firm has a market cap of $239.34 million, a price-to-earnings ratio of 37.29 and a beta of 0.33. Electromed has a 12 month low of $13.74 and a 12 month high of $35.56. The stock has a fifty day moving average price of $31.40 and a 200-day moving average price of $25.41.

Institutional Trading of Electromed

Several large investors have recently added to or reduced their stakes in ELMD. Russell Investments Group Ltd. purchased a new stake in Electromed during the 4th quarter valued at about $37,000. IFP Advisors Inc purchased a new stake in Electromed during the 4th quarter valued at about $59,000. Quantbot Technologies LP purchased a new stake in Electromed during the 4th quarter valued at about $99,000. Bank of America Corp DE grew its stake in Electromed by 179.2% during the 4th quarter. Bank of America Corp DE now owns 4,004 shares of the company’s stock valued at $118,000 after purchasing an additional 2,570 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in Electromed during the 4th quarter valued at about $119,000. Hedge funds and other institutional investors own 40.82% of the company’s stock.

Insider Buying and Selling

In related news, Director Andrew Summers sold 12,731 shares of the business’s stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $29.98, for a total transaction of $381,675.38. Following the transaction, the director now directly owns 165,755 shares in the company, valued at $4,969,334.90. The trade was a 7.13 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Kathleen Skarvan sold 38,954 shares of the business’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $29.28, for a total value of $1,140,573.12. Following the transaction, the director now owns 32,622 shares in the company, valued at approximately $955,172.16. This trade represents a 54.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 77,788 shares of company stock worth $2,326,350 in the last ninety days. 14.00% of the stock is owned by insiders.

Electromed Company Profile

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.